50.20CHF-3.65%Mkt Cap: 621.21M CHFP/E: 15.99Last update: 2026-06-01
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap621.21M CHF
Enterprise Value569.81M CHF
Revenue (TTM)232.38M CHF
Gross Profit193.06M CHF
Net Income (TTM)40.24M CHF
Revenue/Share18.98 CHF
Last Price50.20 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees189
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447
Valuation
P/E (Trailing)15.99
P/E (Forward)12.53
PEG-0.08
EV/EBITDA10.54
EV/Revenue2.45
P/S2.77
P/B5.01
EPS (TTM)3.12
EPS (Forward)4.16
52W Range
44.1039% of range59.70
52W High59.70 CHF
52W Low44.10 CHF
Profitability
Gross Margin83.08%
Oper. Margin21.70%
EBITDA Margin23.27%
Profit Margin17.32%
ROE31.45%
ROA14.27%
Growth
Revenue Growth-2.90%
Earnings Growth-55.20%
Cash Flow & Leverage
Operating CF62.09M CHF
CapEx (TTM)2.86M CHF
FCF Margin21.15%
FCF Yield7.91%
Net Debt-70.58M CHF
Net Debt/EBITDA-1.31
Balance Sheet
Debt/Equity0.70
Current Ratio5.12
Quick Ratio4.53
Book Value/Sh10.41 CHF
Cash/Share13.00 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 11, 2013
Pay Date—
Analyst Consensus
Rating—
Target (Mean)89.90 CHF
Target Range59.40 CHF – 120.00 CHF
# Analysts6
Ownership
Shares Out.12.37M
Float12.21M
Insiders0.62%
Institutions29.83%
Technical
SMA 5053.88 (-6.8%)
SMA 20051.52 (-2.6%)
Beta0.41
S&P 52W Chg27.70%
Avg Vol (30d)26.06K
Avg Vol (10d)24.93K
Technical Indicators
RSI (14)37.6
MACD-0.3896
MACD Signal-0.1442
MACD Hist.-0.2454
BB Upper55.97 CHF
BB Middle54.02 CHF
BB Lower52.08 CHF
BB Width7.21%
ATR (14)1.434 CHF
Vol Ratio (20d)1.29x